In recent years there is a huge leap of pharma industry towards rare diseases and orphan drug developments due to the great support from regulatory authorities such as faster approval timelines, supportive regulatory frameworks, financial incentives, and many more. Currently, large pharmaceutical companies are extremely active in the orphan drugs market. Novartis, GSK, Roche, and […]

Read More →

Revised Chinese regulations that brought a lot of changes in clinical trials and product registrations were received with lots of questions. If you have got questions that are yet unanswered, you are not alone. Many researchers, developers and managers are not sure about one aspect or another on how to comprehend, act or change their […]

Read More →

Do you know any product segment, where one does not get to encounter Chinese products? Well, hardly any. It has been the focus of Chinese government for the past several decades to dominate various industrial sectors, including pharmaceuticals. While, China has been the big production factory for generic drugs and API ingredients for many years, […]

Read More →